IUPHAR/BPS Guide to Pharmacology CITE
https://doi.org/10.2218/gtopdb/F260/2019.4

Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Chen Yan[1]

1. University of Rochester, USA

Abstract

3',5'-Cyclic nucleotide phosphodiesterases (PDEs, 3',5'-cyclic-nucleotide 5'-nucleotidohydrolase), E.C. 3.1.4.17, catalyse the hydrolysis of a 3',5'-cyclic nucleotide (usually cyclic AMP or cyclic GMP). isobutylmethylxanthine is a nonselective inhibitor with an IC_{50} value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2',3'-cyclic nucleotide 3'-phosphodiesterase (E.C. 3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS.

Contents

This is a citation summary for Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts.

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs)
http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=260

- Enzymes
  - PDE1A(phosphodiesterase 1A)
    http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1294
  - PDE1B(phosphodiesterase 1B)
    http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1295
  - PDE1C(phosphodiesterase 1C)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1296

PDE2A(phosphodiesterase 2A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1297

PDE3A(phosphodiesterase 3A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1298

PDE3B(phosphodiesterase 3B)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1299

PDE4A(phosphodiesterase 4A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

PDE4B(phosphodiesterase 4B)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

PDE4C(phosphodiesterase 4C)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1302

PDE4D(phosphodiesterase 4D)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

PDE5A(phosphodiesterase 5A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304

PDE6A(phosphodiesterase 6A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1312

PDE6B(phosphodiesterase 6B)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1313

PDE6C(phosphodiesterase 6C)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1314

PDE6D(phosphodiesterase 6D)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1315

PDE6G(phosphodiesterase 6G)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1316

PDE6H(phosphodiesterase 6H)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1317

PDE7A(phosphodiesterase 7A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1305

PDE7B(phosphodiesterase 7B)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1306

PDE8A(phosphodiesterase 8A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1307

PDE8B(phosphodiesterase 8B)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1308

PDE9A(phosphodiesterase 9A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1309

PDE10A(phosphodiesterase 10A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1310

PDE11A(phosphodiesterase 11A)

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1311

References

1. Adams JL, Smothers J, Srinivasan R and Hoos A. (2015) Big opportunities for small molecules in immuno-oncology. *Nat Rev Drug Discov* **14**: 603-22 [PMID:26228631]
2. Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR and Plattner JJ. (2009) Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. *Bioorg. Med. Chem. Lett.*

19: 2129-32 [PMID:19303290]

3. Alaamery MA, Wyman AR, Ivey FD, Allain C, Demirbas D, Wang L, Ceyhan O and Hoffman CS. (2010) New classes of PDE7 inhibitors identified by a fission yeast-based HTS. *J Biomol Screen* **15**: 359-67 [PMID:20228279]
4. Albrecht W, Unger A, Bauer SM and Laufer SA. (2017) Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases. *J. Med. Chem.* **60**: 5290-5305 [PMID:28613871]
5. Allcock RW, Blakli H, Jiang Z, Johnston KA, Morgan KM, Rosair GM, Iwase K, Kohno Y and Adams DR. (2011) Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast. *Bioorg. Med. Chem. Lett.* **21**: 3307-12 [PMID:21530250]
6. Aoki M, Kobayashi M, Ishikawa J, Saita Y, Terai Y, Takayama K, Miyata K and Yamada T. (2000) A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. *J. Pharmacol. Exp. Ther.* **295**: 255-60 [PMID:10991987]
7. Basole CP, Nguyen RK, Lamothe K, Vang A, Clark R, Baillie GS, Epstein PM and Brocke S. (2017) PDE8 controls $CD4^+$ T cell motility through the PDE8A-Raf-1 kinase signaling complex.*Cell. Signal.* **40**: 62-72 [PMID:28851628]
8. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A and Koenig G. (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. *Neuropharmacology* **47**: 1081-92 [PMID:15555642]
9. Boyle CD, Xu R, Asberom T, Chackalamannil S, Clader JW, Greenlee WJ, Guzik H, Hu Y, Hu Z and Lankin CM *et al.*. (2005) Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED. *Bioorg. Med. Chem. Lett.* **15**: 2365-9 [PMID:15837326]
10. Ceyhan O, Birsoy K and Hoffman CS. (2012) Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen. *Chem. Biol.* **19**: 155-63 [PMID:22284362]
11. Clerin V, Gale J and Tamimi N.. (2014) Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy. Patent number: WO-2014064566-A1.
12. Corbin JD, Turko IV, Beasley A and Francis SH. (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. *Eur. J. Biochem.* **267**: 2760-7 [PMID:10785399]
13. Edmondson SD, Mastracchio A, He J, Chung CC, Forrest MJ, Hofsess S, MacIntyre E, Metzger J, O'Connor N and Patel K *et al.*. (2003) Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors. *Bioorg. Med. Chem. Lett.* **13**: 3983-7 [PMID:14592490]
14. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA and Phillips SC. (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. *Proc. Natl. Acad. Sci. U.S.A.* **97**: 3702-7 [PMID:10725373]
15. Fisher DA, Smith JF, Pillar JS, St Denis SH and Cheng JB. (1998) Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. *Biochem. Biophys. Res. Commun.* **246**: 570-7 [PMID:9618252]
16. Fisher DA, Smith JF, Pillar JS, St Denis SH and Cheng JB. (1998) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. *J. Biol. Chem.* **273**: 15559-64 [PMID:9624146]
17. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K and Omori K. (1999) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). *J. Biol. Chem.* **274**: 18438-45 [PMID:10373451]
18. Gardner C, Robas N, Cawkill D and Fidock M. (2000) Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. *Biochem. Biophys. Res. Commun.* **272**: 186-92 [PMID:10872825]
19. Gharat LA, Gopalan B and Khairatkar-Joshi N. (2006) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders. Patent number: WO2006064355A2.

20. Guay D, Boulet L, Friesen RW, Girard M, Hamel P, Huang Z, Laliberté F, Laliberté S, Mancini JA and Muise E *et al.*. (2008) Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. *Bioorg. Med. Chem. Lett.* **18**: 5554-8 [PMID:18835163]
21. Hanifin JM, Ellis CN, Frieden IJ, Fölster-Holst R, Stein Gold LF, Secci A, Smith AJ, Zhao C, Kornyeyeva E and Eichenfield LF. (2016) OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. *J. Am. Acad. Dermatol.* **75**: 297-305 [PMID:27189825]
22. Hayashi M, Matsushima K, Ohashi H, Tsunoda H, Murase S, Kawarada Y and Tanaka T. (1998) Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase. *Biochem. Biophys. Res. Commun.* **250**: 751-6 [PMID:9784418]
23. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ and Houslay MD. (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. *EMBO J.* **18**: 893-903 [PMID:10022832]
24. Hoffmann R, Wilkinson IR, McCallum JF, Engels P and Houslay MD. (1998) cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. *Biochem. J.* **333 (Pt 1)**: 139-49 [PMID:9639573]
25. Houslay MD and Adams DR. (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. *Biochem. J.* **370**: 1-18 [PMID:12444918]
26. Huang Z, Dias R, Jones T, Liu S, Styhler A, Claveau D, Otu F, Ng K, Laliberte F and Zhang l*et al.*. (2007) L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. *Biochem. Pharmacol.* **73**: 1971-81 [PMID:17428447]
27. Hughes RO, Walker JK, Rogier DJ, Heasley SE, Blevis-Bal RM, Benson AG, Jacobsen EJ, Cubbage JW, Fobian YM and Owen DR *et al.*. (2009) Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one. *Bioorg. Med. Chem. Lett.* **19**: 5209-13 [PMID:19631533]
28. Jones GH, Venuti MC, Alvarez R, Bruno JJ, Berks AH and Prince A. (1987) Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide. *J. Med. Chem.* **30**: 295-303 [PMID:3027338]
29. Kodimuthali A, Jabaris SS and Pal M. (2008) Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. *J. Med. Chem.* **51**: 5471-89 [PMID:18686943]
30. Korkmaz-Icöz S, Radovits T and Szabó G. (2018) Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. *Br. J. Pharmacol.* **175**: 223-231 [PMID:28213937]
31. Loughney K, Martins TJ, Harris EA, Sadhu K, Hicks JB, Sonnenburg WK, Beavo JA and Ferguson K. (1996) Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases. *J. Biol. Chem.* **271**: 796-806 [PMID:8557689]
32. Lunniss CJ, Cooper AW, Eldred CD, Kranz M, Lindvall M, Lucas FS, Neu M, Preston AG, Ranshaw LE and Redgrave AJ *et al.*. (2009) Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. *Bioorg. Med. Chem. Lett.* **19**: 1380-5 [PMID:19195882]
33. Martinez GR, Walker KA, Hirschfeld DR, Bruno JJ, Yang DS and Maloney PJ. (1992) 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. *J. Med. Chem.* **35**: 620-8 [PMID:1311763]
34. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J and Manganiello VC. (2014) Advances in targeting cyclic nucleotide phosphodiesterases. *Nat Rev Drug Discov* **13**: 290-314 [PMID:24687066]
35. Meanwell NA, Pearce BC, Roth HR, Smith EC, Wedding DL, Wright JJ, Buchanan JO, Baryla UM, Gamberdella M and Gillespie E *et al.*. (1992) Inhibitors of blood platelet cAMP phosphodiesterase. 2.

Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains. *J. Med. Chem.* **35**: 2672-87 [PMID:1321910]

36. Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA and Wigler M. (1993) Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. *J. Biol. Chem.* **268**: 12925-32 [PMID:8389765]
37. Michie AM, Lobban M, Müller T, Harnett MM and Houslay MD. (1996) Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. *Cell. Signal.* **8**: 97-110 [PMID:8730511]
38. Mochida H, Takagi M, Inoue H, Noto T, Yano K, Fujishige K, Sasaki T, Yuasa K, Kotera J and Omori K *et al.*. (2002) Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. *Eur. J. Pharmacol.* **456**: 91-8 [PMID:12450574]
39. Mohamed HA, Girgis NM, Wilcken R, Bauer MR, Tinsley HN, Gary BD, Piazza GA, Boeckler FM and Abadi AH. (2011) Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. *J. Med. Chem.* **54**: 495-509 [PMID:21189023]
40. Moslin R, Gardner D, Santella J, Zhang Y, Duncia JV, Liu C, Lin J, Tokarski JS, Strnad J and Pedicord D *et al.*. (2017) Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling. *Medicinal Chemistry Communications* **8**: 700-712
41. Okada M, Kato M, Sato N, Uno T, Kitagaki H, Haruta J, Hiyama H and Shibata T. (2007) Oxazole compound and pharmaceutical composition Patent number: WO2007058338.
42. Perry MJ, O'Connell J, Walker C, Crabbe T, Baldock D, Russell A, Lumb S, Huang Z, Howat D and Allen R *et al.*. (1998) CDP840: a novel inhibitor of PDE-4.*Cell Biochem Biophys.* **29**: 113-32 [PMID:9631241]
43. Rawson DJ, Ballard S, Barber C, Barker L, Beaumont K, Bunnage M, Cole S, Corless M, Denton S and Ellis D *et al.*. (2012) The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. *Bioorg. Med. Chem.* **20**: 498-509 [PMID:22100260]
44. Saldou N, Obernolte R, Huber A, Baecker PA, Wilhelm R, Alvarez R, Li B, Xia L, Callan O and Su Q *et al.*. (1998) Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. *Cell. Signal.* **10**: 427-40 [PMID:9720765]
45. Sasaki T, Kotera J, Yuasa K and Omori K. (2000) Identification of human PDE7B, a cAMP-specific phosphodiesterase. *Biochem. Biophys. Res. Commun.* **271**: 575-83 [PMID:10814504]
46. Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI and Chopra R. (2014) Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. *Cell. Signal.* **26**: 2016-29 [PMID:24882690]
47. Sircar I, Steffen RP, Bobowski G, Burke SE, Newton RS, Weishaar RE, Bristol JA and Evans DB. (1989) Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. *J. Med. Chem.* **32**: 342-50 [PMID:2536438]
48. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS and Giembycz MA. (2004) Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. *Mol. Pharmacol.* **66**: 1679-89 [PMID:15371556]
49. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y and Hidaka H. (2000) Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. *Biochem. Pharmacol.* **59**: 347-56 [PMID:10644042]
50. Tsai YF, Chu TC, Chang WY, Wu YC, Chang FR, Yang SC, Wu TY, Hsu YM, Chen CY and Chang SH *et al.*. (2017) 6-Hydroxy-5,7-dimethoxy-flavone suppresses the neutrophil respiratory burst via selective PDE4 inhibition to ameliorate acute lung injury. *Free Radic. Biol. Med.* **106**: 379-392 [PMID:28263828]
51. Turko IV, Ballard SA, Francis SH and Corbin JD. (1999) Inhibition of cyclic GMP-binding cyclic GMP-

specific phosphodiesterase (Type 5) by sildenafil and related compounds. *Mol. Pharmacol.* **56**: 124-30 [PMID:10385692]

52. Vemulapalli S, Watkins RW, Chintala M, Davis H, Ahn HS, Fawzi A, Tulshian D, Chiu P, Chatterjee M and Lin CC *et al.*. (1996) Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. *J. Cardiovasc. Pharmacol.* **28**: 862-9 [PMID:8961086]
53. Venhuis BJ, Zomer G, Hamzink M, Meiring HD, Aubin Y and de Kaste D. (2011) The identification of a nitrosated prodrug of the PDE-5 inhibitor aildenafil in a dietary supplement: a Viagra with a pop. *J Pharm Biomed Anal* **54**: 735-41 [PMID:21145686]
54. Venuti MC, Jones GH, Alvarez R and Bruno JJ. (1987) Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856). *J. Med. Chem.* **30**: 303-18 [PMID:3027339]
55. Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F and O'Connor R *et al.*. (2009) Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. *J. Med. Chem.* **52**: 5188-96 [PMID:19630403]
56. Wang G, Liu Z, Chen T, Wang Z, Yang H, Zheng M, Ren J, Tian G, Yang X and Li J *et al.*. (2012) Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. *J. Med. Chem.* **55**: 10540-50 [PMID:23137303]
57. Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW and Billah MM. (1997) Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. *Biochem. Biophys. Res. Commun.* **234**: 320-4 [PMID:9177268]
58. Wang P, Wu P, Ohleth KM, Egan RW and Billah MM. (1999) Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. *Mol. Pharmacol.* **56**: 170-4 [PMID:10385698]
59. Wilson LS and Brandon NJ. (2015) Emerging biology of PDE10A.*Curr. Pharm. Des.* **21**: 378-88 [PMID:25159072]
60. Yang SW, Smotryski J, McElroy WT, Tan Z, Ho G, Tulshian D, Greenlee WJ, Guzzi M, Zhang X and Mullins D *et al.*. (2012) Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. *Bioorg. Med. Chem. Lett.* **22**: 235-9 [PMID:22142545]